Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00110929|
Recruitment Status : Completed
First Posted : May 17, 2005
Last Update Posted : April 23, 2010
|Condition or disease||Intervention/treatment||Phase|
|End Stage Renal Disease||Drug: AMG 073||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||850 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) When Two Different Vitamin D Regimens Are Used in Subjects With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)|
|Study Start Date :||November 2002|
- Examine PTH and Ca x P control when cinacalcet is administered in the setting of flexible dosing of vitamin D sterols.
- Examine safety and tolerability of cinacalcet.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00110929